Market revenue in 2020 | USD 235.5 million |
Market revenue in 2028 | USD 507.9 million |
Growth rate | 10.1% (CAGR from 2020 to 2028) |
Largest segment | Reagent-based |
Fastest growing segment | Reagent-based |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagent-based, Physical Disruption |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 62.12% in 2020. Horizon Databook has segmented the Canada cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
Canada is estimated to witness lucrative growth owing to extensive R&D in the field of biosimilars, vaccines, antibodies, and other bio therapeutics. Moreover, several local players are also engaged in expanding their footprints in the competitive markets.
This was one of the first pegfilgrastim biosimilars approved by a Canadian regulatory body. This would lead to market growth over the forecast period as cell disruption and lysis is an important step in downstream processing of biosimilars.
Moreover, government initiatives to support developments in genetic, proteomic, and metabolomics studies are projected to drive the country’s progress. For instance, in 2018, Genome Canada, a nonprofit organization active in the field of genome-based technologies.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell lysis and disruption market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account